84 related articles for article (PubMed ID: 18041358)
1. Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study.
Prezioso D; Bartoletti R; Cecchi M; Cicalese V; Cunico SC; Damiano R; De Lisa A; Franzolin N; Frea B; Guazzoni G; Mearini E; Morgia G; Muzzonigro G; Oliva G; Orestano F; Pagliarulo A; Pappagallo GL; Parma P; Perachino M; Pompa P; Rocco F; Zattoni F;
Arch Ital Urol Androl; 2007 Sep; 79(3):99-103. PubMed ID: 18041358
[TBL] [Abstract][Full Text] [Related]
2. Hormonal treatment for prostate cancer in Italy. Preliminary data from a survey of the QUABIOS Group.
Prezioso D; Pappagallo GL; Guazzoni G; Orestano F; Zattoni F;
Arch Ital Urol Androl; 2006 Mar; 78(1):15-9. PubMed ID: 16752882
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.
Curigliano G; Spitaleri G; De Cobelli O; Scardino E; Sbanotto A; de Braud F
Urol Int; 2009; 82(2):196-202. PubMed ID: 19322010
[TBL] [Abstract][Full Text] [Related]
4. Combined androgen blockade (CAB) versus luteinizing hormone-releasing hormone (LHRH) agonist monotherapy for androgen deprivation therapy.
Park HS; Shin HB; Woo SH; Jeon SH; Lee SH; Kang SH; Shim JS; Shin DW; Park J
World J Urol; 2020 Apr; 38(4):971-979. PubMed ID: 31187203
[TBL] [Abstract][Full Text] [Related]
5. [Quality of life of patients with prostate cancer under androgen deprivation with GnRH analogues: Results of the noninterventional study TRIPTOSIX].
Eisenhardt A; Schneider T; Scheithe K; Colling C; Heidenreich A;
Urologe A; 2016 Feb; 55(2):176-83. PubMed ID: 26518305
[TBL] [Abstract][Full Text] [Related]
6. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
7. Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with prostate cancer - EORTC QLQ-PR25.
Park J; Shin DW; Yun SJ; Park SW; Jeon SS; Kwak C; Kwon TG; Kim HJ; Ahn H
Oncology; 2013; 85(5):299-305. PubMed ID: 24217330
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.
Irani J; Salomon L; Oba R; Bouchard P; Mottet N
Lancet Oncol; 2010 Feb; 11(2):147-54. PubMed ID: 19963436
[TBL] [Abstract][Full Text] [Related]
9. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
10. Intermittent androgen suppression in the treatment of metastatic prostate cancer.
Bouchot O; Lenormand L; Karam G; Prunet D; Gaschignard N; Malinovsky JM; Buzelin JM
Eur Urol; 2000 Nov; 38(5):543-9. PubMed ID: 11096234
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS).
Lazzaro C; Bartoletti R; Guazzoni G; Orestano F; Pappagallo GL; Prezioso D; Zattoni F;
Arch Ital Urol Androl; 2007 Sep; 79(3):104-7. PubMed ID: 18041359
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.
Schröder FH; Collette L; de Reijke TM; Whelan P
Br J Cancer; 2000 Jan; 82(2):283-90. PubMed ID: 10646878
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
14. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of maximal androgen blockade in prostate cancer patients at a health area with type 2 reference hospital. Part 2. Quality of life: application of EORTC QLQ-PR25 instrument and global results. Quality-of-life adjusted survival. Pharmaceutical expenses and cost-utility.
Guerra NA
Arch Esp Urol; 2009 Sep; 62(7):543-70. PubMed ID: 19815968
[TBL] [Abstract][Full Text] [Related]
16. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
[TBL] [Abstract][Full Text] [Related]
17. Impacts of leuprolide acetate on quality of life in patients with prostate cancer: a prospective multicenter study.
You D; Jeong IG; Kim SW; Chung BH; Cho JS; Lee HM; Yun SC; Kim CS
Scand J Urol Nephrol; 2010 Dec; 44(6):399-405. PubMed ID: 20707648
[TBL] [Abstract][Full Text] [Related]
18. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
19. Outcomes from the use of maximal androgen blockade in prostate cancer at health area with reference hospital type 2 (1st part). Quality of life: application of EORTC QLQ-C30 instrument.
Cruz Guerra NA
Arch Esp Urol; 2009 Jul; 62(6):431-57. PubMed ID: 19736374
[TBL] [Abstract][Full Text] [Related]
20. [The treatment of prostatic carcinoma with cyproterone acetate].
Tsvetkov M; Mladenov D; Kumanov Kh
Khirurgiia (Sofiia); 1996; 49(1):12-5. PubMed ID: 8975080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
